@article{c00cb8ec964b4b3b89c62eb3424ba474,
title = "Escitalopram prevents relapse of obsessive-compulsive disorder",
abstract = "To examine the efficacy and tolerability of escitalopram in the prevention of relapse in patients with OCD, 468 patients with OCD were treated with open label escitalopram (10 mg or 20 mg) for 16 weeks, after which the 320 responders (Y-BOCS total score decrease ≥ 25%) were randomised to placebo or escitalopram (at the assigned dose) for 24 weeks double-blind treatment. The primary analysis (time to relapse) showed a significant advantage for escitalopram (p < 0.001, log-rank test). The proportion of patients who relapsed was statistically significantly higher in the placebo group (52%) than in the escitalopram group (23%) (p < 0.001, χ2-test). The risk of relapse was 2.74 times higher for placebo compared to escitalopram. Escitalopram was well tolerated and improvements in obsessive-compulsive symptoms reported during the open label period were sustained during the double-blind extension of treatment with active drug. These results demonstrate that escitalopram is effective for long-term treatment and relapse prevention in OCD.",
keywords = "Escitalopram, OCD, Obsessive-compulsive disorder, Relapse prevention, Y-BOCS, Yale-Brown Obsessive Compulsive Scale",
author = "Fineberg, {Naomi A.} and Brigitte Tonnoir and Ole Lemming and Stein, {Dan J.}",
note = "Funding Information: The authors gratefully acknowledge the contribution of the investigators in each of the centres in this study: Australia (48 patients) : Mike Theodoros, Isaac Schweitzer, David Barton, Graham Burrows, Kevin McNamara, Austria (55 patients) : Siegfried Kasper, Margot Schmitz, Hartmann Hinterhuber, Georg Sch{\"o}nbeck, Canada (38 patients) : Martin Tremblay, Guy Debonnel, Angelo Fallu, Jacques Plamondon, John Pecknold, Satpal Girgla, Martin Katzman, Hungary (100 patients) : Gabriella Agoston, Katalin Hideg, Sandor Koffler, Gy{\"o}rgy Ostorharics, Attila Nemeth, Israel (59 patients) : Mendel Fux, Haggai Hermesh, Ilana Kremer, Miki Bloch, Joseph Zohar, Ehud Klein, Italy (8 patients) : Filippo Bogetto, Alberto Siracusano, Malaysia (47 patients) : Ahmad Hatim Sulaiman, Azhar Md Zain, Mohd Ariff Bin Mohd Noor, Teck Hoe Yen, Norway (13 patients) : Sverre Hougsnaes, Torbj{\o}rn Sigurdson, Jan Wimpelmann, Hilde Th{\o}rnquist, Philippines (17 patients) : Cynthia Leynes, Roberto Capistrano, Monina Cruz, Dino Pena, Portugal (3 patients) : Mario Lourenco, Singapore (5 patients) : Adrian Wang, South Africa (45 patients) : Catherine Maud, Paul Strong, David Dennis, Greta Brinks, Annemarie Potgieter, Ian Westmore, Hilda Russouw, Dora Wynchank, Paresh U, Ramjee, Karien Botha, Thailand (14 patients) : Nipatt Karnjanathanalers, Sunanta Chantarujikapong, Ngamwong Jaruraisin, United Kingdom (16 patients) : Paul Fletcher, John Ryan, Paul McEleny, Martin Adler. NA Fineberg and DJ Stein have received honoraria from, and have conducted clinical research supported by H. Lundbeck A/S. B Tonnoir and O. Lemming are fulltime employees of H. Lundbeck A/S. ",
year = "2007",
month = may,
doi = "10.1016/j.euroneuro.2006.11.005",
language = "English",
volume = "17",
pages = "430--439",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "6-7",
}